# Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

> **NCT05927142** · PHASE1,PHASE2 · RECRUITING · sponsor: **Joachim Aerts, MD PhD** · enrollment: 43 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Rintatolimod

## Key facts

- **NCT ID:** NCT05927142
- **Lead sponsor:** Joachim Aerts, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-09
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05927142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05927142, "Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05927142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*